The Biogen Inc., headquarters is shown in March 11, 2020, in Cambridge, Mass. Cost cutting helped Biogen beat second-quarter expectations soundly, Wednesday, July 20, 2022, even as revenue slid and sales of the drugmaker’s controversial Alzheimer’s treatment collapsed. Aduhelm, a drug once expected to generate billions in annual sales, brought in only $100,000 in the quarter. (AP Photo/Steven Senne, file)